These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325 [TBL] [Abstract][Full Text] [Related]
5. [Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11]. Klautke G; Fietkau R Strahlenther Onkol; 2002 Mar; 178(3):163-4. PubMed ID: 11962194 [No Abstract] [Full Text] [Related]
6. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Erlichman C; Goldberg RM; O'Connell MJ N Engl J Med; 2001 Jan; 344(4):305; author reply 306-7. PubMed ID: 11191661 [No Abstract] [Full Text] [Related]
7. Colorectal cancer: to stack or sequence therapy? Azvolinsky A J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957442 [No Abstract] [Full Text] [Related]
8. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736 [TBL] [Abstract][Full Text] [Related]
9. Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma. Kallen KJ; Hofmann MA; Timm A; Gödderz W; Galle PR; Heike M Z Gastroenterol; 2000 Feb; 38(2):153-7. PubMed ID: 10721170 [TBL] [Abstract][Full Text] [Related]
10. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039 [TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer. Yao Y; Sun YJ; Zhao H; Guo YW; Lin F; Cai X; Tang XC; Tang LN; Zhang W Chin Med J (Engl); 2006 Nov; 119(21):1829-33. PubMed ID: 17097039 [No Abstract] [Full Text] [Related]
12. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809 [TBL] [Abstract][Full Text] [Related]
13. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer. Dohn LH; Jensen BV; Larsen FO Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495 [No Abstract] [Full Text] [Related]
14. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492 [TBL] [Abstract][Full Text] [Related]
15. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940 [TBL] [Abstract][Full Text] [Related]
16. [Progress of chemotherapy in colorectal cancer]. Komatsu Y Gan To Kagaku Ryoho; 2007 Nov; 34(11):1771-6. PubMed ID: 18064761 [No Abstract] [Full Text] [Related]
18. Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose. Vincent M; Ho C; Tomiak A; Winquist E; Whiston F; Stitt L Clin Colorectal Cancer; 2002 Aug; 2(2):111-8. PubMed ID: 12453326 [TBL] [Abstract][Full Text] [Related]
19. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076 [TBL] [Abstract][Full Text] [Related]
20. Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment? Idelevich E; Man S; Lavrenkov K; Gluzman A; Geffen DB; Shani A J Chemother; 2004 Oct; 16(5):487-90. PubMed ID: 15565917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]